Form D · Pharmaceuticals
Vaneltix Pharma, Inc.
New Brunswick, NJ · CIK 0000932352
Offering snapshot reported Jan 24, 2024 · SEC filing
- Reported sold
- $1M Offering amount: $5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 12, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 24, 2024 | Initial | $1,000,000 | No comparison | 6 | SEC filing |
| Nov 20, 2020 | Initial | $3,021,843 | No comparison | 32 | SEC filing |
| Feb 7, 2018 | Initial | $1,377,000 | No comparison | 22 | SEC filing |
| Apr 13, 2017 | Initial | $500,000 | No comparison | 5 | SEC filing |
| Jul 14, 2015 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Oct 4, 2013 | Amendment | $856,000 | $106,000vs Jul 19, 2013 | 17 | SEC filing |
| Jul 19, 2013 | Initial | $750,000 | No comparison | 12 | SEC filing |
| Jun 5, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 30, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-503265
Source: Form D, filed Jan 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carlo Di Fonzo | Director |
| Robert Lowell Evans | Director |
| Michael Goldberg | Director |
| Abe Hahn | Director |
| A. Luc Maasdorp | Director |
| Michael Nordlicht | Director |
| C. Lowell Parsons | Director |
| Mark J. Rosenblum | Executive |
| Daniel Vickery | Director, Executive |
| Dan Vickery | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
317 George Street Suite 400
New Brunswick, NJ, 08901
New Brunswick, NJ, 08901